Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
J6 · Effective Oct 1, 2015
3 active Medicare policies list J2777, and 19 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J6 · Effective Jan 1, 2026
19 policies from 14 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2777 |
|---|---|---|
| Faricimab-svoa (Vabysmo)Effective 03/01/2023 - 12/31/2023 | Mar 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Faricimab-svoa (Vabysmo)Effective 06/01/2022 - 07/18/2022 | Jun 1, 2022 | Prior auth requiredInferred from policy title |
| Vabysmo (faricimab-svoa intravitreal) | Not recorded | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vabysmo (faricimab-svoa intravitreal)Effective 06/01/2024 - 05/31/2025 | Jun 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vabysmo (faricimab-svoa intravitreal)Effective 06/01/2025 - 05/31/2026 | Jun 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Vabysmo (faricimab-svoa)Effective 01/01/2024 - 05/31/2024 | Jan 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2777 |
|---|---|---|
| Non-Bevacizumab Vascular Epithelial Growth Factors for Ophthalmic Use (e.g., Beovu, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Pavblu, Vabysmo, Enzeevu, Ahzantive, Yesafili, Opuviz) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Faricimab-svoa | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Faricimab-svoa | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Faricimab-svoa | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Faricimab-svoa | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2777 |
|---|---|---|
| VABYSMO (FARICIMAB-SVOA) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Faricimab-svoa (Vabysmo) | Jun 30, 2022 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Vabysmo (faricimab-svoa) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Faricimab-svoa (Vabysmo) ; CP.PHAR.581 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Vabysmo (faricimab-svoa) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J2777 |
|---|---|---|
| Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors | Jul 1, 2026 | Covered |